Matches in SemOpenAlex for { <https://semopenalex.org/work/W2043288748> ?p ?o ?g. }
- W2043288748 abstract "In a minority of cancer patients immunotherapy has shown the capacity to eradicate tumours leading to clinical remission and the promise of a cure. In the majority of patients however, a cure remains elusive due to active immune evasion by cancers; HLA-down-regulation and immunosuppression are two of the known mechanisms adopted by cancers to promote their survival and proliferation. To overcome these challenges we have developed bi-specific soluble biologics termed ImmTACs (Immune mobilising mTCR against cancer) to re-direct the immune system to recognise and kill cancers. Antigenic peptide fragments presented by HLA molecules on the surface of cancer cells constitute the largest class of cancer associated targets. T cells scan the HLA-peptide (pHLA) antigens being presented to them; sufficient recognition by the harboured T Cell Receptor (TCR) will result in T cell activation and killing of the antigen presenting cell. In cancer patients this process is inefficient partly due to the low affinity TCRs expressed by tumour specific T cells and the low abundance of pHLA on cancers. ImmTACs comprise a soluble TCR with an enhanced affinity for cancer associated pHLA (targeting end) fused to an anti-CD3 scfv, enabling potent T cell re-direction (effector end). Our pipeline constitutes a number of ImmTACs targeting various antigen pHLA complexes relevant to numerous cancer indications. IMCmage1 is a novel ImmTAC targeting MAGE-A3168-176 in the context of HLA-A1. MAGE-A3 is a well validated cancer testis antigen expressed in a variety of cancers including myeloma, NSCLC, prostate cancer, melanoma, bladder cancer, oesophageal cancer and others. IMCmage1 re-directs T cells from cancer patients or healthy donors to kill a range of MAGE positive cell-lines in vitro; this activity is observed against cells presenting as few as 40 epitopes per cell and is coupled with the release of pro-inflammatory cytokines including IFNα, TNFα, IL-2, MIP1α and others. We also demonstrate that IMCmage1 specifically targets and kills the myeloma associated population within CD138+ cells extracted from the marrow of a stage III myeloma patient. IMCmage1 specificity was confirmed by exposure to a panel of HLA-A1 MAGE negative primary cells derived from various organs such as the heart, skin, lung and others; no significant activity was detected. A phase I clinical trial in multiple myeloma to assess tolerability and establish a maximum tolerated dose is planned to commence in Q2 2012. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3528. doi:1538-7445.AM2012-3528" @default.
- W2043288748 created "2016-06-24" @default.
- W2043288748 creator A5005393076 @default.
- W2043288748 creator A5008558372 @default.
- W2043288748 creator A5015290004 @default.
- W2043288748 creator A5016957205 @default.
- W2043288748 creator A5029346258 @default.
- W2043288748 creator A5029353304 @default.
- W2043288748 creator A5029606221 @default.
- W2043288748 creator A5032425529 @default.
- W2043288748 creator A5036470230 @default.
- W2043288748 creator A5037746795 @default.
- W2043288748 creator A5040315117 @default.
- W2043288748 creator A5046543435 @default.
- W2043288748 creator A5055515556 @default.
- W2043288748 creator A5055997013 @default.
- W2043288748 creator A5062031466 @default.
- W2043288748 creator A5064842058 @default.
- W2043288748 creator A5071548337 @default.
- W2043288748 creator A5072070089 @default.
- W2043288748 creator A5076011877 @default.
- W2043288748 creator A5080115238 @default.
- W2043288748 creator A5086811457 @default.
- W2043288748 creator A5088946297 @default.
- W2043288748 creator A5090274252 @default.
- W2043288748 creator A5091470129 @default.
- W2043288748 creator A5091784705 @default.
- W2043288748 date "2012-04-15" @default.
- W2043288748 modified "2023-09-25" @default.
- W2043288748 title "Abstract 3528: IMCmage1: A novel bi-specific biologic re-directing T cells to kill MAGE-A3/A6 presenting cancers" @default.
- W2043288748 doi "https://doi.org/10.1158/1538-7445.am2012-3528" @default.
- W2043288748 hasPublicationYear "2012" @default.
- W2043288748 type Work @default.
- W2043288748 sameAs 2043288748 @default.
- W2043288748 citedByCount "0" @default.
- W2043288748 crossrefType "proceedings-article" @default.
- W2043288748 hasAuthorship W2043288748A5005393076 @default.
- W2043288748 hasAuthorship W2043288748A5008558372 @default.
- W2043288748 hasAuthorship W2043288748A5015290004 @default.
- W2043288748 hasAuthorship W2043288748A5016957205 @default.
- W2043288748 hasAuthorship W2043288748A5029346258 @default.
- W2043288748 hasAuthorship W2043288748A5029353304 @default.
- W2043288748 hasAuthorship W2043288748A5029606221 @default.
- W2043288748 hasAuthorship W2043288748A5032425529 @default.
- W2043288748 hasAuthorship W2043288748A5036470230 @default.
- W2043288748 hasAuthorship W2043288748A5037746795 @default.
- W2043288748 hasAuthorship W2043288748A5040315117 @default.
- W2043288748 hasAuthorship W2043288748A5046543435 @default.
- W2043288748 hasAuthorship W2043288748A5055515556 @default.
- W2043288748 hasAuthorship W2043288748A5055997013 @default.
- W2043288748 hasAuthorship W2043288748A5062031466 @default.
- W2043288748 hasAuthorship W2043288748A5064842058 @default.
- W2043288748 hasAuthorship W2043288748A5071548337 @default.
- W2043288748 hasAuthorship W2043288748A5072070089 @default.
- W2043288748 hasAuthorship W2043288748A5076011877 @default.
- W2043288748 hasAuthorship W2043288748A5080115238 @default.
- W2043288748 hasAuthorship W2043288748A5086811457 @default.
- W2043288748 hasAuthorship W2043288748A5088946297 @default.
- W2043288748 hasAuthorship W2043288748A5090274252 @default.
- W2043288748 hasAuthorship W2043288748A5091470129 @default.
- W2043288748 hasAuthorship W2043288748A5091784705 @default.
- W2043288748 hasConcept C121608353 @default.
- W2043288748 hasConcept C126322002 @default.
- W2043288748 hasConcept C147483822 @default.
- W2043288748 hasConcept C151730666 @default.
- W2043288748 hasConcept C19317047 @default.
- W2043288748 hasConcept C203014093 @default.
- W2043288748 hasConcept C2776090121 @default.
- W2043288748 hasConcept C2777701055 @default.
- W2043288748 hasConcept C2779343474 @default.
- W2043288748 hasConcept C2780192828 @default.
- W2043288748 hasConcept C2780674031 @default.
- W2043288748 hasConcept C502942594 @default.
- W2043288748 hasConcept C71924100 @default.
- W2043288748 hasConcept C86803240 @default.
- W2043288748 hasConcept C8891405 @default.
- W2043288748 hasConcept C96232424 @default.
- W2043288748 hasConceptScore W2043288748C121608353 @default.
- W2043288748 hasConceptScore W2043288748C126322002 @default.
- W2043288748 hasConceptScore W2043288748C147483822 @default.
- W2043288748 hasConceptScore W2043288748C151730666 @default.
- W2043288748 hasConceptScore W2043288748C19317047 @default.
- W2043288748 hasConceptScore W2043288748C203014093 @default.
- W2043288748 hasConceptScore W2043288748C2776090121 @default.
- W2043288748 hasConceptScore W2043288748C2777701055 @default.
- W2043288748 hasConceptScore W2043288748C2779343474 @default.
- W2043288748 hasConceptScore W2043288748C2780192828 @default.
- W2043288748 hasConceptScore W2043288748C2780674031 @default.
- W2043288748 hasConceptScore W2043288748C502942594 @default.
- W2043288748 hasConceptScore W2043288748C71924100 @default.
- W2043288748 hasConceptScore W2043288748C86803240 @default.
- W2043288748 hasConceptScore W2043288748C8891405 @default.
- W2043288748 hasConceptScore W2043288748C96232424 @default.
- W2043288748 hasLocation W20432887481 @default.
- W2043288748 hasOpenAccess W2043288748 @default.
- W2043288748 hasPrimaryLocation W20432887481 @default.
- W2043288748 hasRelatedWork W1953817170 @default.
- W2043288748 hasRelatedWork W1989175760 @default.
- W2043288748 hasRelatedWork W2011173404 @default.
- W2043288748 hasRelatedWork W2036038128 @default.